According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

See part one of Imogen’s pregnancy diary which reveals why she was dumbstruck when she found out she was pregnant here.

Stock analysts at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Anavex Life Sciences in ...

Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $42 from $52 and keeps an Outperform rating on the shares. The firm ...